- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02954302
Proximal Roux-en-y Gastrojejunal Anastomosis on Delayed Gastric Emptying After Pylorus-resecting Pancreaticoduodenectomy
Proximal Roux-en-y Gastrojejunal Anastomosis on Delayed Gastric Emptying After Pylorus-resecting Pancreaticoduodenectomy: A Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Fujian
-
Xiamen, Fujian, China, 361003
- Recruiting
- First Affiliated Hospital of Xiamen University
-
Contact:
- Minqiang Lin, Dr
- Phone Number: 8605922139908 8605922139708
- Email: 80218353@qq.com
-
Principal Investigator:
- Yanming Zhou, Dr
-
Sub-Investigator:
- Xiaofeng Zhang, Dr
-
Sub-Investigator:
- Feng Yu, Dr
-
Sub-Investigator:
- Lupeng Wu, Dr
-
Sub-Investigator:
- AIling Song, Dr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients who were scheduled to undergo PD and provided written informed consent.
- In the opinion of the surgeon, the subject has no medical contraindications to PD.
- At least 18 years of age.
Exclusion Criteria:
- Patients who underwent other surgical procedures than PD, such as total pancreatectomy (TP) or a palliative biliary and gastroenteric anastomosis.
- Drug abusers or alcoholics.
- Patient who have previous transabdominal surgery.
- The patient who were scheduled to undergo laparoscopic PD.
- The patient who does not want to participate the clinical trials.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: PrPD with RGA
Patients who will undergo PrPD with proximal Roux-en-y gastrojejunal anastomosis.
|
the distal antrum was divided about 1 to 2 cm proximal to the pylorus ring, preserving more than 95% of the stomach.
The proximal jejunum was divided approximately 2 to 4 cm distal to the duodeno-jejunal junction.
After completion of the resection, the proximal end of the first loop of jejunum was then brought through the transverse mesocolon, and the gastrojejunal anastomosis (GJA) was performed in two layers by using 3-0 PDS sutures and 4-0 silk sutures in an end-to-side fashion.
The jejunum was then divided 35 to 40 cm distal to the GJA, and the distal limb was brought separately through the transverse mesocolon to be placed in the duodenal bed for reconstruction of the pancreatojejunal anastomosis (PJA) and hepatojejunal anastomosis (HJA).
|
|
Experimental: conventional PrPD
Patients who will undergo conventional PrPD.
|
After completion of the pancreatojejunal anastomosis (PJA) and hepatojejunal anastomosis (HJA), a hand-sewn, isoperistaltic GJA was performed 25 to 30 cm distal to the HJA in two layers by using 3-0 polydioxanone (PDS) sutures and 4-0 silk sutures.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Delayed gastric emptying,rate
Time Frame: 60 days after operation
|
The severity of DGE was classified into 3 grades (A, B, or C) according to the ISGPS's clinical criteria, based on the patient's clinical course and postoperative management, such as the need for NGT in the postoperative period or the inability to tolerate solid oral intake. Grade A was defined as needing the NGT for more than 7 days or reinsertion of the NGT after postoperative day 3, or as being unable to tolerate a solid diet by postoperative day 7. Grade B was defined as needing for NGT for 8 to 14 days after surgery or reinsertion of the NGT after day 7, or as being unable to tolerate a solid diet by postoperative day 14. Grade C was defined as needing the NGT for more than 14 days or reinsertion of the NGT after day 14, or as being unable to tolerate a solid diet by day 21. |
60 days after operation
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Morbidity,rate
Time Frame: 60 days after operation
|
60 days after operation
|
|
Mortality,rate
Time Frame: 60 days after operation
|
60 days after operation
|
|
Length of hospital stay,days
Time Frame: 60 days after operation
|
60 days after operation
|
|
Pancreatic fistula,rate
Time Frame: 60 days after operation
|
60 days after operation
|
|
Hemorrhage,rate
Time Frame: 60 days after operation
|
60 days after operation
|
|
Bile leakage,rate
Time Frame: 60 days after operation
|
60 days after operation
|
|
Intra-abdominal abscess,rate
Time Frame: 60 days after operation
|
60 days after operation
|
|
wound infection,rate
Time Frame: 60 days after operation
|
60 days after operation
|
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
nonsurgical complications,rate
Time Frame: 60 days after operation
|
60 days after operation
|
Collaborators and Investigators
Investigators
- Principal Investigator: Yanming Zhou, Dr, First Affiliated Hospital of Xiamen University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Neurologic Manifestations
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Duodenal Diseases
- Biliary Tract Diseases
- Paralysis
- Bile Duct Diseases
- Biliary Tract Neoplasms
- Cholangiocarcinoma
- Gastroparesis
- Bile Duct Neoplasms
- Duodenal Neoplasms
Other Study ID Numbers
- FAHXMU-2016-04
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.